Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study (Q45070916)
Jump to navigation
Jump to search
scientific article published on 20 October 2017
- Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study |
scientific article published on 20 October 2017 |
|
Statements
1 reference
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study (English)
1 reference
Michael Benatar
1 reference
Ted M Burns
1 reference
Kimiaki Utsugisawa
1 reference
James F Howard
1 reference
Richard J Barohn
1 reference
Richard J Nowak
1 reference
Hiroyuki Murai
1 reference
Isabel Illa
1 reference
Saiju Jacob
1 reference
John Vissing
1 reference
John T Kissel
1 reference
Srikanth Muppidi
1 reference
Fanny O'Brien
1 reference
Jing-Jing Wang
1 reference
REGAIN Study Group
1 reference
20 October 2017
1 reference
1 reference
16
1 reference
12
1 reference
976-986
1 reference
Identifiers
1 reference
1 reference